These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22120644)

  • 1. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
    García-Arieta A; Morales-Alcelay S; Herranz M; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C
    Int J Pharm; 2012 Feb; 423(2):321-5. PubMed ID: 22120644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence studies: single vs multiple dose.
    Steinijans VW; Sauter R; Jonkman JH; Schulz HU; Stricker H; Blume H
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S31-6. PubMed ID: 1601529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An alternative single dose parameter to avoid the need for steady-state studies on oral extended-release drug products.
    Paixão P; Gouveia LF; Morais JA
    Eur J Pharm Biopharm; 2012 Feb; 80(2):410-7. PubMed ID: 22108491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A European perspective on orally inhaled products: in vitro requirements for a biowaiver.
    García-Arieta A
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):419-29. PubMed ID: 25238116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D; Frýbortová K; Rabisková M; Danecková H
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.
    Meredith PA
    Curr Med Res Opin; 2009 Sep; 25(9):2179-89. PubMed ID: 19601710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The need for additional metrics to assess therapeutic equivalence of some multiphasic modified-release products.
    Kondra PM; Endrenyi L; Tothfalusi L
    Clin Ther; 2011 Sep; 33(9):1214-9. PubMed ID: 21849209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viewpoint: observations on scaled average bioequivalence.
    Patterson SD; Jones B
    Pharm Stat; 2012; 11(1):1-7. PubMed ID: 22162308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?
    Dupont AG; Heller F
    Acta Clin Belg; 2009; 64(5):406-14. PubMed ID: 19999388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new European Medicines Agency guideline on the investigation of bioequivalence.
    Morais JA; Lobato Mdo R
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine.
    Yacobi A; Zlotnick S; Colaizzi JL; Moros D; Masson E; Abolfathi Z; LeBel M; Mehta R; Golander Y; Levitt B
    Clin Pharmacol Ther; 1999 Apr; 65(4):389-94. PubMed ID: 10223775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical considerations into the new EMA guideline on bioequivalence.
    Marzo A; Fontana E
    Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
    Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
    Choi SH; Lionberger RA
    AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the impact of partial area under the curve in a bioavailability/bioequivalence study on generic prolonged-release formulations.
    Soares KCC; Chiann C; Storpirtis S
    Eur J Pharm Sci; 2022 Apr; 171():106127. PubMed ID: 35063607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence studies for levothyroxine.
    Bolton S
    AAPS J; 2005 Mar; 7(1):E47-53. PubMed ID: 16146349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.